Researchers at Rockefeller University found that the brain begins an antiviral response within hours after an infection far from the head. Mouse experiments showed signals from infected tissue activate genes in the brain and that early priming can improve survival.
Photo by National Institute of Allergy and Infectious Diseases, Unsplash
A mouse study tracked thousands of B cells across many germinal centers to see how antibodies improve. Using imaging and Deep Mutational Scanning, researchers found selection across centers produces stronger antibodies and may guide vaccine design.
A new study reports that some people with long COVID make autoantibodies that attack brain and nerve tissue. When researchers gave these antibodies to mice, the animals developed pain, fatigue and balance problems similar to patient symptoms.
Researchers at University of Rochester Medicine report that antibiotics given to newborns can alter gut bacteria and reprogram lung immune cells in mice and humans. These changes can last into young adulthood and may affect breathing.
Researchers report a vaccine approach using cell-derived extracellular vesicles that display inverted influenza hemagglutinin proteins. Tests in mice showed broad immune responses after intranasal dosing, suggesting potential for a universal mucosal flu vaccine.
New research finds that some chemotherapy agents can make cancer cells behave like virus‑infected cells. This viral mimicry activates the innate immune system and could let doctors use lower drug doses with better results.
Researchers report a modified oral vaccine made from Listeria that primes immune cells in the gut and limits tumor growth in mice. The vaccine worked best when combined with immune checkpoint inhibitors and caused few side effects.
A Washington State University study found that a lesser-known TWEAK–Fn14 pathway can join with TNF to increase inflammation. Blocking Fn14 reduced this surge and may explain why some patients do not respond to TNF inhibitors.
